Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CYCN 
Cyclerion Therapeutics Inc (CYCN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: CYCN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -76.83% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.88M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 1 | Beta 1.34 | 52 Weeks Range 1.27 - 9.47 | Updated Date 09/15/2025 |
52 Weeks Range 1.27 - 9.47 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.66 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -89.51% | Operating Margin (TTM) -1797.85% |
Management Effectiveness
Return on Assets (TTM) -24.15% | Return on Equity (TTM) -22.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4874142 | Price to Sales(TTM) 3.62 |
Enterprise Value 4874142 | Price to Sales(TTM) 3.62 | ||
Enterprise Value to Revenue 2.24 | Enterprise Value to EBITDA 0.56 | Shares Outstanding 3203310 | Shares Floating 2467574 |
Shares Outstanding 3203310 | Shares Floating 2467574 | ||
Percent Insiders 31.48 | Percent Institutions 11.43 |
Upturn AI SWOT
Cyclerion Therapeutics Inc
Company Overview
History and Background
Cyclerion Therapeutics, Inc. was a clinical-stage biopharmaceutical company that focused on discovering, developing, and commercializing medicines for serious and rare diseases. It was spun out of Ironwood Pharmaceuticals in 2019 and ceased operations in March 2023.
Core Business Areas
- Soluble Guanylate Cyclase (sGC) Stimulators: Focused on developing sGC stimulators to modulate nitric oxide (NO) signaling for therapeutic benefit.
Leadership and Structure
Peter Hecht was the CEO. The company had a typical biotech organizational structure with departments focused on research, development, clinical operations, and finance.
Top Products and Market Share
Key Offerings
- CY6463: A central nervous system (CNS)-penetrant sGC stimulator being developed for Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). It did not reach commercialization. Market share unavailable as it never reached commercialization. Competitors unknown because this condition is so rare that there are no current competing medications.
- Praliciguat: An oral sGC stimulator being developed for sickle cell disease and heart failure with preserved ejection fraction (HFpEF). It did not reach commercialization before the company ceased operations. Market share unavailable as it never reached commercialization. Key competitors that have drugs in the market targeting similar mechanism include: Vericiguat (BAY 1021189).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and regulated. Cyclerion focused on rare diseases, a niche market with high unmet medical needs but also high development risks.
Positioning
Cyclerion positioned itself as an innovator in sGC stimulation. The company focused on developing novel therapies for diseases with high unmet needs.
Total Addressable Market (TAM)
The TAM for the indications Cyclerion was targeting (sickle cell disease, HFpEF, MELAS) was potentially significant (billions of USD). Cyclerion's position was early-stage development, so it was far from capturing any meaningful market share.
Upturn SWOT Analysis
Strengths
- Novel sGC stimulator technology
- Experienced management team
- Focus on rare diseases
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- Lack of marketed products
Opportunities
- Potential for orphan drug designation
- Strategic partnerships
- Expansion to new indications
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Funding limitations
Competitors and Market Share
Key Competitors
- VRTX
- MRK
- BMY
Competitive Landscape
Cyclerion was a small player competing against large, established pharmaceutical companies. Its sGC stimulator technology was its main competitive advantage, but clinical trial success was essential.
Growth Trajectory and Initiatives
Historical Growth: Cyclerion did not achieve commercial-stage growth. Its growth depended on successful clinical trial outcomes.
Future Projections: N/A as the company ceased operations.
Recent Initiatives: The company focused on advancing praliciguat and CY6463 through clinical trials. It attempted to secure additional funding.
Summary
Cyclerion Therapeutics was a high-risk, high-reward biotech company focused on a novel therapeutic target, sGC stimulation. It ceased operations due to its inability to secure additional funding and/or favorable clinical outcomes. Its strengths included its innovative technology and focus on rare diseases, but it faced significant financial and clinical challenges. Ultimately, the company was unable to navigate these challenges successfully and dissolved.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases
- SEC filings
- Industry reports
Disclaimers:
This analysis is based on publicly available information and historical data. It should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cyclerion Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2019-04-02 | CEO, President & Director Dr. Regina M. Graul Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.cyclerion.com |
Full time employees 1 | Website https://www.cyclerion.com | ||
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.